At IDRI, we are the bridge between knowledge and action. We combine passion, understanding of disease and technology to improve the health of the world.
ABOUT IDRI

IDRI is a global health nonprofit institute, with a focus on developing new products to combat the world’s most devastating infectious diseases. We are uniquely positioned, combining the high-quality science of a research organization with the product development capabilities of a biotech company. This product-based approach to fighting infectious diseases is yielding novel diagnostics, drugs and vaccines that are protecting and saving lives around the world.

IDRI’s research and development is primarily focused on three key diseases – leprosy, leishmaniasis and tuberculosis – but its technology and collaborations apply to a variety of other diseases. As a world leader in the development of adjuvants, a key component of modern-day vaccines, IDRI licenses its technologies to partners to create vaccines for diseases ranging from HIV to influenza to malaria.

Headquartered in Seattle, WA, IDRI collaborates with companies, universities, governments and institutions around the world, as we believe the best place to advance new products is in the countries where the diseases we tackle create the highest burden.

BY THE NUMBERS

- Founded: in 1993, by Steven G. Reed, Ph.D.
- Employees: 120, ~40 have advanced degrees; ~90 in research and development
- Annual Budget: $23 million
- Collaborators: 80+ around the world
- Facilities: Headquartered in Seattle’s South Lake Union neighborhood, with 55,000 square feet of general labs, specialized facilities and office space

CAPABILITIES

IDRI has a wide range of capabilities and expertise to support preclinical and clinical programs, with operational infrastructure in place. Our capabilities include:

- Adjuvants and Formulations Development
- Antigen Discovery and Expression
- Clinical/Regulatory Support
- Diagnostic Test Development
- Drug Discovery
- GMP Manufacturing
- Human Immune Monitoring
- Immunology
- Process Sciences
- Quality Assurance/Quality Control Services
- Vaccinology
A Letter from David J. Maki
Chair, Board of Directors

In a world that is still suffering from – and threatened by – infectious disease, IDRI stands out as a unique scientific organization that blends high-quality research and state-of-the-art product development.

Thanks to the innovative vision and leadership of our scientists and management team, IDRI has leveraged these capabilities to engage, enable and empower people all over the world in the quest to eliminate infectious disease and its devastating impact upon the quality of life for women, men and children on virtually every continent.

IDRI’s strategy of enablement brings our expertise and technology in drugs, diagnostics and vaccines to local and regional organizations, providing the tools for in-country development and production.

Looking ahead, I can assure you that we remain determined to use all of our technical expertise, diligence and personal commitment to make the world safer and more secure from infectious disease. We invite you to help support our mission of enabling people, communities, companies and healthcare providers throughout the world as we all seek improved health and greater independence for the most disadvantaged in our world.

Sincerely,
David J. Maki
A Letter from Steven G. Reed, Ph.D.

Founder, President & Chief Scientific Officer

IDRI was founded with one goal in mind: to fill unmet needs by developing products that will save lives from being lost to the world’s most devastating infectious diseases. During the past 21 years, we have had success in reaching that goal, particularly in the field of diagnostics. But there is much more work to be done for diseases we’ve been battling for decades, as well as newly emerging diseases.

We cannot do this work alone. We believe our most valuable development partners are those who are on the ground in the countries where infectious diseases – tuberculosis, HIV, leishmaniasis and leprosy, to name a few – are most prevalent. We are engaging and empowering these partners to harness IDRI’s technology to help solve global health challenges in their communities and beyond.

As you read this report, you’ll learn how this strategy of empowerment is rolling out, taking hold and making a difference – from India to Brazil to South Africa and beyond. You’ll also read about our successes over the past year as our vaccines move forward in clinical trials, our drug discovery efforts continue and our diagnostics are being used in the field.

Most importantly, I hope you’ll see your role in IDRI’s success. Thanks to you – our donors, partners, colleagues and funders – we are transforming science into global health solutions.

Sincerely,

Steven G. Reed

Having a great idea is easy. Turning that idea into reality is tough, but the results save lives. This is what IDRI is all about.
Early in his career, Steve Reed developed an affinity for the country of Brazil, where he was researching infectious diseases and managing an international medicine program as a Cornell University medical school faculty member.

“Brazil is a country that is wealthy in many ways, but not necessarily in terms of health,” he said. “Being there catalyzed my desire to work in the field of global health when I saw the great potential of the country and its people being held back by the lack of tools to prevent, diagnose and treat infectious diseases.”

Recognizing the Need
His experience working closely with people afflicted by debilitating illnesses in Brazil brought to light the urgent need for easy-to-use products, particularly diagnostics. Reed speaks of seeing children being forcibly held down for highly invasive and painful tests to determine infection of leishmaniasis, a parasitic disease that comes in various forms, which can lead to death or social stigma.

Recognizing the need, Reed knew there had to be a better solution and an idea took shape. In order to turn his idea into reality, IDRI was born. Reed founded IDRI in 1993 with the vision of gathering a team of world-class scientists who would bridge innovative scientific research with product development to positively impact the prevention, detection and treatment of infectious disease.

Products on the Market
Fast forward to 2014 and IDRI has a pipeline of scientific products in place to improve the health of the world. “Even the most successful biotech companies would be envious of the pipeline that IDRI has developed,” said Stewart Parker, member of IDRI’s Board of Directors.

One of IDRI’s flagship products is “rk-39,” a diagnostic test that came about as a direct result of the need Reed saw all those years ago in Brazil. Developed to detect leishmaniasis infection, the test is quick, easy and accurate—requiring a single drop of blood. It is deployed around the world and is often administered free. For example, the government of Bangladesh provides this test free of charge throughout the country. IDRI’s technology is also used to detect Chagas disease and leprosy infection.

Now, IDRI is taking the next steps to fulfill its mission by transferring its technology into emerging markets so solutions can be developed in the countries where the need is greatest.
Empowering

With good health comes a world of possibilities: the ability to get an education, take care of a family, hold a job or contribute to society. But often health is blocked by the onslaught of infectious diseases, causing death and debilitation. IDRI is devoted to providing knowledge, technology and products that will lead to new solutions for these diseases. This is how we empower others.

Individuals

In a remote village in Brazil, a woman sits, surrounded by her family, in a mud hut with no electricity as children cheerfully call to one another outside.

Last year, she lost her daughter to leishmaniasis, which is particularly problematic for women and children, as are many infectious diseases.

This year, the woman, her family and members of her village are being tested for leishmaniasis with a diagnostic developed using IDRI’s technology. Easily used in even the most remote areas, the test is simple, requiring a single drop of blood, and quick, with results coming in just 10 minutes.

On this one day, nearly 100 people in the village are tested. Those who tested positive were immediately started on a regimen of drugs, setting them on the course for a healthier future.

Countries

A country of incredible natural beauty, culture and talents, South Africa has much to offer. Unfortunately, the country is also home to one of the most severe tuberculosis (TB) epidemics in the world, with an estimated half a million new cases of TB every year. The South African government is partnering with IDRI to change that – and to develop new solutions for diseases that plague the African continent.

In a move to transfer vaccine technology into countries that have the highest infectious disease burden, IDRI has created a new company in Cape Town, South Africa. The company will use IDRI’s vaccine technologies to innovate and develop much-needed new vaccines, including IDRI’s TB vaccine candidate currently in the clinical testing phases.

Funding for the new company comes primarily from the Industrial Development Corp., a financial institution owned by the South African government that promotes economic growth and industrial development. “We believe this unique model can be replicated with success in other countries,” said Erik Iverson, President, Business & Operations.

“It is health that is real wealth and not pieces of gold and silver.” – Mahatma Gandhi
Companies

One of the most devastating infectious diseases in India is visceral leishmaniasis (VL), a parasitic disease that can be fatal if left untreated.

There is currently no vaccine, but life-long immunity generated in patients who self-cure offers promise that an effective vaccine is possible. IDRI’s VL candidate vaccine, LEISH-F3+GLA-SE (developed with funding from the Bill & Melinda Gates Foundation) recently completed Phase 1 clinical studies in healthy, uninfected adults in the U.S. “The vaccine candidate was safe and induced a strong immune response,” said Rhea Coler, Ph.D., IDRI’s Vice President of Preclinical Biology. “This data provided a strong rationale for additional trials in endemic countries with populations particularly vulnerable to VL.”

Now, a unique partnership IDRI has formed with Zydus, India’s fourth largest healthcare group, provides the next step toward an effective VL vaccine. Zydus and IDRI are collaborating to conduct clinical activities in India with the goal of developing, registering and marketing IDRI’s vaccine candidate for the prevention of VL, while ensuring the vaccine is affordable and accessible to all.
Enabling

Cutting-edge scientific research and state-of-the-art product development must enable people around the world to address their own health problems.

That’s the thinking behind IDRI’s current strategy, which is designed to assist countries like South Africa, Brazil and India in developing, producing and distributing essential disease-fighting tools, which will improve health, while providing jobs and enhancing economies.

Technology Transfer to Develop In-Country

Three years ago in India, for example, IDRI joined forces with a local company, Gennova, to set up a production center that would make clinical-grade vaccine materials to develop and produce a range of vaccines. Today, the production center is fully functional.

Two years ago, IDRI started discussions to create a new company in South Africa. The company will initially use IDRI technology to innovate areas of vaccine development for infectious diseases, with an emphasis on TB. “In the end, we will see vaccines created and produced in South Africa by South Africans for South Africans – and we hope to replicate this model throughout Africa in coming years,” said IDRI’s Steve Reed.

The story is similar in Brazil, where IDRI is working with the Brazilian government on technology transfers for TB, leprosy and leishmaniasis.
“These local initiatives,” said IDRI’s Erik Iverson, “will also help improve the health of workers in crucial industries like coffee, mining, oil and gas and cocoa throughout Africa and South America. And that’s definitely a prosperity-builder.”

**Rapid Response: The Need for Speed**

In addition to providing technologies for use in-country, there is an additional component needed to enable better health around the world. “We have to stop the next outbreak of infectious disease with a rapid and effective response,” said Franklyn G. Prendergast, M.D., a member of IDRI’s Board of Directors and professor at the Mayo Medical School. “With today’s ease of mobility, diseases could travel the world in less than 24 hours.”

“The good news in this scenario is reflected in IDRI’s latest scientific research studies,” explained Darrick Carter, Ph.D., Vice President of Adjuvant Technology at IDRI. “We now know that we can efficiently produce more powerful vaccines that protect a greater number of people than ever before.”

Key to these next-generation vaccines are adjuvants, which trigger and enhance the immune response in order to boost their effectiveness, versatility and reach. Adjuvants improve a vaccine’s reach through economical “dose sparing” – reducing the amount of vaccine needed for a dose, which lowers the cost of the vaccine per person and increases the number of patients who can be protected by the currently available supply. For example, clinical studies using IDRI’s adjuvants in flu vaccine candidates show that in terms of dosage, when adjuvant compounds were used, one shot of flu vaccine could actually do the work of two.

“The bottom line is that, in order to anticipate and deal with a disease outbreak, we need to have components like adjuvants at the ready and stockpiled, so that we can rapidly build a vaccine response,” said Reed.
While freeze-drying is often associated with food, the process – called lyophilization – is also used for another life-saving activity: vaccines. Freeze-drying a vaccine increases its shelf life and addresses the issue of maintaining a temperature-controlled supply chain – the so-called “cold chain.”

Through lyophilization, IDRI scientists are developing vaccine candidates that can be implemented throughout the world without being hampered by the necessity of a continuous cold chain or separate antigen/adjuvant vials.

Today’s next-generation, rationally designed vaccines contain both an antigen (which stimulate antibodies in the immune system to combat infectious agents) and an adjuvant (substances added to vaccines to enhance the ability of antigens to stimulate the body’s immune response). However, the two components are kept in separate vials that must be mixed in exact proportions just in advance of the vaccine being administered, and cold-chain process must be maintained for long-term stability.

In late 2013, IDRI researchers published results in the Journal of Controlled Release, describing the development and characterization of a tuberculosis vaccine, comprised of both antigen and adjuvant components that were stable in a single vial at sustained elevated temperatures. Best of all, the vaccine retained its ability to protect against Mycobacterium tuberculosis, the bacterium that causes TB.

Training for the Future

While a team effort, IDRI’s work in lyophilization highlighted contributions by some of the youngest members of the team who served as co-authors on the publication: Lucien Barnes, who joined IDRI in 2010 as a research associate, just after graduating from Western Washington University with a bachelor’s degree in Cellular & Molecular Biology/Biochemistry, and Quinton Dowling, who came to IDRI in 2009 after graduating from the College of Idaho with a bachelor’s degree in Chemistry/Biology.

Growing up in Washington where he “lived in the woods and played on the beach,” Barnes developed an early love for nature and biology. But, when he
was 12, his father died from hepatitis C, turning his focus on how he could help people. In college, he worked in a lab focused on aspergillus, a fungus that infects food stock like grains and seeds and produces a lethal toxin. “This was a huge issue in the developing world – there was an entire village in Africa that got wiped out because this fungus infected the corn supply,” Barnes said. That cemented his desire to help people by working in the field of global health.

Barnes has been accepted into a Ph.D. program at the University of California, Santa Barbara, where he’ll study molecular, cellular and developmental biology. He ultimately hopes to “continue along the vaccine route,” because of interest stimulated during his time at IDRI. “Being able to take a really fragile vaccine and stabilize it through freeze-drying takes the guess-work out of whether or not the vaccine will be viable when it’s delivered,” he said. “And, if a vaccine is stable, it can be taken all over the world.”

Much like Barnes, Dowling’s love of nature fueled his love of science. “I was into animals and plants as a kid;” he said. He credits his high school, Seattle Academy, with furthering his interest in science, as well as awakening a sense of social responsibility. After spending time as a fly fishing guide in Alaska following college graduation, Dowling came to IDRI to work in process development. “I’m exploring adjuvants from physical properties all the way down to fundamental chemistry,” he said. “We can zoom in and out and probe at different levels to understand a variety of different things about the immune system and the mechanisms of how adjuvants “degrade.” This information was applied to IDRI’s work on lyophilization – showing that vaccines could remain stable at high temperatures over time. As Dowling continues his work at IDRI, his long-term plans are to earn a Ph.D. – or maybe a M.D./Ph.D. – in bioengineering. He believes IDRI’s environment that encourages learning by doing will help pave the way for him in the future.

Barnes’ and Dowling’s stories are familiar at IDRI and one the organization is proud to play a role in: providing a proving ground for budding young scientists – from undergraduate interns to postdoctoral graduates – to learn side-by-side with some of the best infectious disease researchers in the world and use what they’ve learned to springboard into the next phase of their career.
Findings a Cure for HIV

HIV remains one of the world’s most daunting diseases, and IDRI is providing partners with adjuvants for use in HIV vaccine candidates. In 2014, IDRI took another step in the fight against HIV, becoming the fiscal sponsor for an exciting new alliance, the HIV Cure Initiative, which brings together an international group of leading scientific, governmental, philanthropic and industrial organizations. The goal is to develop new pathways to amplify existing efforts to cure HIV, with a commitment to overcome barriers to success through greater collaboration.

A New Home for IDRI

In 2013, IDRI moved from its long-time residence in Seattle’s First Hill neighborhood to its new home at 1616 Eastlake Avenue East, occupying approximately 55,000 square feet, principally on the fourth floor of the building. The majority of the space contains general laboratories, as well as specialized facilities including a GMP manufacturing suite (which is home to state-of-the-art technology allowing for automatic fill/finish of products), rooms for drug discovery robotics and a Human Immune Monitoring Center. Over the past year, IDRI welcomed hundreds of visitors for interactive tours throughout the lab space, showcasing our work.

Animal Health is Global Health

Because animal health is so closely related to human health – about 60 percent of human pathogens have an animal origin – it’s important to battle infectious diseases in the animal population. IDRI has partnered with Elanco, Eli Lilly’s veterinary product company, to develop new vaccines against major veterinary diseases, including livestock diseases that pose a potential threat to food sources. As part of this unique partnership, IDRI is developing new vaccines and diagnostics for a range of animal diseases, using IDRI’s expertise in adjuvants.
New Hope for Leprosy Prevention

Currently, there is no vaccine to prevent leprosy, a devastating infectious disease that is found in 115 countries. Now, IDRI scientists, in collaboration with clinical research groups in the Philippines and Brazil and with funding from the American Leprosy Missions, have prioritized human T cell antigens to develop the world’s first defined leprosy vaccine. Called LepVax, the vaccine candidate consists of validated antigens and a clinical grade adjuvant, both developed by IDRI. Proof-of-concept experiments validated IDRI’s candidate vaccine, showing that it is ready to be moved forward to toxicology testing, followed by Phase 1 clinical trials in human volunteers in 2015.

TB Vaccine Moves Forward

Initial results from the first Phase 1 clinical trial of IDRI’s novel TB vaccine candidate, ID93 + GLA-SE, show promising safety and immunogenicity data. Conducted in close collaboration with Aeras with funding from the Bill & Melinda Gates Foundation, the trial assessed the safety, tolerability and immunogenicity of the vaccine in 60 healthy adult volunteers in the U.S. with no prior exposure to BCG (the vaccine currently given to prevent TB, which is only partially effective) or Mycobacterium tuberculosis (Mtbb), the bacterium that causes TB. The Paul G. Allen Family Foundation provided funding to IDRI for clinical development in preparation for the trial, and the National Institutes of Health provided funding to IDRI for preclinical development of the ID93 + GLA-SE vaccine. In another IDRI/Aeras partnership, IDRI’s TB vaccine candidate is currently in a Phase 1 clinical trial in South Africa in 66 healthy adult volunteers; each person has been BCG vaccinated and may/may not be latently infected with Mtbb. This trial is assessing the safety, tolerability and immunogenicity within these specific populations.

Screening for TB Drugs

IDRI’s Tuberculosis Discovery efforts have reached an important landmark: researchers in that program have now screened more than half a million compounds, seeking hits for potential new drugs to combat TB, which kills nearly 1.5 million each year and infects about one-third of the world’s population. Earlier this year, Tanya Parish, Ph.D., IDRI’s Vice President of Drug Discovery, received a grant extension of $3.4 million from the Bill & Melinda Gates Foundation to continue the identification of new leads and drug targets for tuberculosis with the ultimate goal of producing new drugs to treat TB. IDRI is a founding member of the Lilly TB Drug Discovery Initiative – headquartered at IDRI – and the TB Drug Accelerator (TBDA). The Lilly initiative is a unique public-private partnership with Eli Lilly and Company and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), with a focus on the discovery of new anti-tuberculosis drugs. The TBDA was founded as a partnership of seven pharmaceutical companies and five other organizations, funded in part by the Bill & Melinda Gates Foundation, to target the discovery of new TB drugs by collaborating on early-stage drug discovery for tuberculosis.
Erik Iverson, JD, LLM  
**President, Business & Operations**

At IDRI, we have a proven track record of spinning out our technologies in order to help promising start-up biotechnology companies. And the resulting licensing revenues have traditionally supported our charitable mission and scientific programs.

But now we’re diversifying our efforts.

That means zeroing in on manufacturing services, and doing even more to transfer our know-how and technology to emerging markets around the world.

---

**Our Team**

**BOARD OF DIRECTORS**

Bruce Carter, Ph.D.  
Christopher Hentschel, Ph.D.  
Erik Iverson, JD, LLM  
David J. Maki, JD  
Chair  
H. Stewart Parker, MBA  
David Perry, MBA  
Franklyn G. Prendergast, M.D., Ph.D.  
Massimo Radaelli, Ph.D.  
Steven G. Reed, Ph.D.  
David Webster, MBA  
Secretary & Treasurer

**EXECUTIVE LEADERSHIP**

Anna Marie Beckmann, Ph.D.  
Vice President, Development & Regulatory  
Darrick Carter, Ph.D.  
Vice President, Adjuvant Technology  
Gail Cassell, Ph.D.  
Vice President, Preclinical Biology  
Rhea N. Coler, Ph.D.  
Vice President, TB Drug Development  
Erik H. Iverson, JD, LLM  
President, Business & Operations  
Karen Kinch  
Vice President, Administration  
Andy Leon, JD, Ph.D.  
Vice President, Operations & Senior Patent Counsel  
Rob Lin, Ph.D., CFA  
Vice President, Finance  
Tanya Parish, Ph.D.  
Vice President, Drug Discovery  
Steven G. Reed, Ph.D.  
Founder, President & Chief Scientific Officer  
Thomas Vedvick, Ph.D.  
Vice President, Formulation & Process Development

**Our Team**

**IDRI Expands Manufacturing Capabilities**

Since 2007, IDRI has been manufacturing small lots of vaccine components (antigens and adjuvants) for preclinical studies, as well as Phase 1 and 2 clinical trials, supporting our own vaccine development needs as well as those of partners around the world.

As IDRI moved into its new facility in 2013, we built out a 4,000-square-foot, state-of-the-art cGMP manufacturing facility. This year, IDRI dramatically expanded its manufacturing capabilities – more than 10 times the former capacity – by adding new technology for automated filling, stoppering and capping.

Product scopes include large and small molecules in liquid formulations, vaccines (non-viral) and adjuvants in liquid forms, emulsions and liposomes. Complex adjuvant formulations based on emulsions and liposomes have been part of IDRI’s core expertise for more than 10 years.

“At IDRI, we partner for small-scale formulation and aseptic filling of liquid, emulsion and liposome products, in compliance with both US and EU regulations,” said Erik Laursen, director of GMP Operations. “Our services are individualized and flexible based on our own needs, as well as those of our partners.”
Our goal is to empower local communities on just about every continent, so they can develop and produce products, and, in the process, strengthen and build their own economies.

There are three basic ways that IDRI has begun empowering local communities around the world:

First, by granting the rights to some of our most innovative technologies. For example, we recently introduced the South Korean government to a game-changing Israeli-made micro-needle device that allows painless intradermal TB testing.

Second, by helping to establish stand-alone health companies in emerging markets that will be operated and run by local citizens. In South Africa, for instance, we’re delivering our intellectual property, knowledge and technology in order to set up the country’s first locally owned vaccine biotechnology company. We’re also hopeful this approach could be taken in other countries, like Brazil.

And, third, by establishing on-the-ground diagnostic production companies to bolster the health of local workers in a host of crucial industries that are vital to the economic well being of emerging countries.

Looking forward, we’ll keep diversifying our efforts – and we’ll keep using our technology to help empower local communities throughout the world as they seek improved health and greater prosperity.

Financials

Funding Sources

By Disease

By Activity

Balance Sheet

Statement

2013 2012

ASSETS
Total Current Assets 20,556,533 31,871,965
Property & equipment, net 15,707,680 9,478,710
Pledges receivable - long term 8,367,475 7,972,481
Investment - long term 583,000 215,000
Total Assets 45,214,688 49,538,156

LIABILITIES & NET ASSETS
Accounts payable & accrued expenses 1,503,405 2,445,651
Deferred rent & unearned revenues 1,627,960 708,029
Total current liabilities 3,131,365 3,153,680
Deferred rent - long term 16,744,525 8,976,741
Total Liabilities 19,875,890 12,130,421

Net Assets
Unrestricted 276,042 3,085,312
Temporarily Restricted 25,062,756 34,322,423
Total Net Assets 25,338,798 37,407,735

Total Liabilities & Net Assets 45,214,688 49,538,156

REVENUES
Public Support 6,685,429 7,517,219
Private grants & contributions 14,319,401 13,845,150
Earned Income 1,646,456 3,089,456
Investment & other revenues 204,240 442,209
Total Revenues 22,855,526 24,894,034

EXPENSES
Program expenses 19,952,713 20,000,794
Management & general expenses 5,424,242 4,412,113
Fundraising 287,851 304,135
Total Expenses 25,664,806 24,717,042

Change in Unrestricted Net Assets (2,809,280) 176,992

FOR THE YEAR ENDING DECEMBER 31, 2013
Audited financial statements are available upon request or on our website at www.idri.org.
Our philanthropic partners – individuals, families, foundations and companies – play a key role in IDRI’s success. Through their contributions, IDRI continues to transform our science into global health solutions to save and improve lives.

Anonymous (2)
Sherry Adams
Aedas
Andy Anderson
Fred & Thuan Angeles
Cheryl & Chris Antony
Mary Rae Armantout
Bill & Pamela Ayer
Rip Ballou & Alice Grasset
Kristin Beaulieu
Behnke Foundation
Paul Blair
Gregg & Jane Blodgett
BNBuilders
Ryan Brown
Brook Byers
Delphi Chatterjee
Ines & Jay Clark
Rebecca Clark
Jessica Cohen
Rhea & Clark Coler
Genevieve Cseh
Brian Curtis
Walter Curtis
Erik Cutts
Steve Davis
Jeff Dixon
Ken Duncan & Tanya Parish
Mary Dunnam
Sharon Early
Eric Easom
Steve Eirschle
Jean Feagin
Norman Ferrer
Edmee Files
Fischer Scientific
Robert Gallo
Joshua Halverson
Fred Hapgood
Cynthia Healy
Erik & Jennifer Iverson
Ed Kesicki
Karen Kinch
Aaron Korkegian
Edward Lanphier
Kenneth Lee
Robert Lin
James R. Lisbakken
LNGC
David & Susan Maki
Curt & Ana Malloy
Karina Martens
Microsoft Matching Gift Program
Morrison Foerster
Jennifer & Mike Mortensen
Erik Nilsson
Mary North Travel
Kelly O’Malley
Yulia Ovechkina
Lynda Paleshnui
Cherry Parish
Gina Parish
Stewart Parker
Elizabeth R. & William J. Patterson Foundation
Molly Pengra
Jeremy Peterson
Jon Peterson
Trang Pham
Franklyn G. Prendergast
Marianne & Steve Reed
Lee & Will Schoentrup
Sandlin Sequin
Laura Shoemaker & Morgan Woolverton
Silicon Valley Bank
Carolyn Booth Stanson
Susan Steinbach-Molloy
George & Carolyn Steiner Family Foundation
Giles Strekel
Robert van Lier
Thomas & Claudia Vedvick
David Webster
Wells Fargo Insurance Services
Winston Wicomb
Ying Yu

To learn more about supporting IDRI’s global health mission, please contact development@idri.org.
Abbvie Laboratories
Chicago, IL

Academia Sinica
Taipei, Taiwan

Addis Ababa University
Addis Ababa, Ethiopia

Aeras
Rockville, MD

Afrigen Biologics
Cape Town, South Africa

Anacor Pharmaceuticals
Palo Alto, CA

Anandaban Hospital
Kathmandu, Nepal

Baylor College of Medicine
Houston, TX

Bio-Rad
Canton, OH

Bio Veto Test
La Seyne-sur-Mer, France

Broad Institute
Cambridge, MA

Cantacuzino Institute
Bucharest, Romania

Case Western Reserve University
Cleveland, OH

Cebu Leprosy and Tuberculosis Research Foundation
Cebu, Philippines

Centers for Disease Control and Prevention
Atlanta, GA

Chembio Diagnostics Systems, Inc.
Medford, NY

Colorado State University
Fort Collins, CO

CTK Biotech, Inc.
San Diego, CA

Duke University
Durham, NC

EASE-Medtrend
Shanghai, China

Elanco
Indianapolis, IN

Eli Lilly and Co.
Indianapolis, IN

European Vaccine Initiative
Heidelberg, Germany

Fraunhofer Center for Molecular Biotechnology
Newark, NJ

Gennova Biopharmaceuticals
Pune, India

Heidelberg Universitat
Heidelberg, Germany

ICDDR,B
Dhaka, Bangladesh

Immune Design Corporation
Seattle, WA

Imperial College London
London, England

InBios International
Seattle, WA

Institute of Biophysics Chinese Academy of Sciences
Beijing, China

Institute of Human Virology
Baltimore, MD

Instituto Butantan
Sao Paulo, Brazil

Instituto De Biomedicina
Caracas, Venezuela

Instituto De Infectologia
Emilio Ribas
Sao Paulo, Brazil

Institute of Endemic Diseases
Khartoum, Sudan

Istituto Superiore di Sanita
Rome, Italy

Jubilant Chemsys
Uttar Pradesh, India

Laboratory of Malaria Immunology and Vaccinology/NIH
Rockville, MD

Laboratory of Malaria and Vector Research/NIH
Rockville, MD

Louisiana State University Veterinary School of Medicine
Baton Rouge, LA

Malaria Cell Biology Section/NIAID/NIH
Rockville, MD

McGill University
Montreal, Canada

Massachusetts Institute of Technology
Cambridge, MA

MCRF/Institute of Microbial Chemistry
Tokyo, Japan

Medicago
Quebec, Canada

Merck
Whitehouse Station, NJ

Merital
Duluth, GA, & Lyon, France

NanoPass
Nes Ziona, Israel

National Hansen’s Disease Program
Baton Rouge, LA

National Institute of Infectious Diseases
Tokyo, Japan

OrangeLife
Rio de Janeiro, Brazil

Oswaldo Cruz Foundation-FIOCRUZ
Rio de Janeiro, Brazil

PECET Universidad De Antioquia
Medellin, Colombia

Radboud University Medical Center
Nijmegen, Netherlands

Ragon Institute
Cambridge, MA

Research Triangle International
Research Triangle Park, NC

Rockefeller University
New York, NY

Sabin Vaccine Institute
Washington, DC

Seattle BioMed
Seattle, WA

South African Tuberculosis Vaccine Initiative
Cape Town, South Africa

Span Diagnostics
Surat, India

Statens Serum Institute
Copenhagen, Denmark

St. George’s University of London
London, England

TDR | World Health Organization
Geneva, Switzerland

Texas A&M
College Station, TX

Texas Tech University Health Sciences Center
Lubbock, TX

Ubio
Kerala, India

UK Consortium on AIDS and International Development
London, England

UK HIV Vaccine Consortium
London, England

Universidad del Valle
Cali, Colombia

Universidad Peruana Cayetano Heredia
Lima, Peru

Universidade Federal Da Bahia
Salvador, Brazil

Universidade Federal De Goias
Goias, Brazil

Universidade Federal De Minas Gerais
Belo Horizonte, Brazil

Universidade Federal De Sergipe
Sergipe, Brazil

Universidade Federal De Uberlandia
Uberlandia, Brazil

University of Banaras
Varanasi, India

University of Copenhagen
Copenhagen, Denmark

University of Delhi
Delhi, India

University of Hawaii
Honolulu, HI

University of Iowa
Iowa City, IO

University of Kentucky
Lexington, KY

University of Texas Medical Branch
Galveston, TX

University of Tokyo
Tokyo, Japan

University of Washington
Seattle, WA

USAID
Washington, DC

Walter & Eliza Hall Institute
Melbourne, Australia

Walter Reed Army Institute of Research
Silver Spring, MD

Weill Cornell Medical College
New York, NY

Zydus Cadila
Ahmedabad, India
Now, we invite you to engage in this mission and consider how you can contribute. It’s easy.

• Tell someone about what you’ve learned as you read IDRI’s Annual Report.
• Visit our web site at www.idri.org, where you can sign up for our electronic newsletter and read our latest blog post.
• Follow us – and comment – on social media: Facebook, Twitter, LinkedIn.
• Attend an IDRI event or take interactive lab tour.
• Invite an IDRI scientist to speak at an educational or civic event.
• Support our research and product development through a donation.

With good health comes a world of possibilities: thriving families, flourishing communities and stable economies.

Throughout this report, you’ve read about IDRI’s work to provide individuals, companies and even countries with the tools and technologies needed to improve the health of the world.
MISSION

We apply innovative science to develop products to eliminate infectious diseases of global importance.

VISION

We envision a world in which infectious diseases are either prevented or rapidly diagnosed and treated using products that are available to all people.

WE VALUE

Compassion: We are driven by compassion and the belief that all people should be free from infectious diseases, which cause untold death and suffering. Our work holds the promise of saving millions of lives and improving the quality of life around the world.

Scientific Excellence: We are rooted in scientific excellence. We are committed to the diligence, integrity and ethics required to conduct research and develop products in a responsible, efficient manner.

Impact: We believe our research and product development will have significant, positive impact for the benefit of the world’s most underserved populations. Through collaboration and innovation, we bridge knowledge and action to reduce suffering and save lives.